Cd. Riffkin et al., MODULATION OF THE FUNCTION OF HUMAN MDR1 P-GLYCOPROTEIN BY THE ANTIMALARIAL DRUG MEFLOQUINE, Biochemical pharmacology, 52(10), 1996, pp. 1545-1552
MDR1 P-glycoprotein in membranes of human tumor cells of the CEM/VBL(1
00) line was selectively labelled using photoreactive analogs of verap
amil, N-(p-azido-3-[I-125]salicyl)amino-verapamil ([I-125]ASA-V) and p
razosin, l)piperazin-1-yl]4-amino-6,7-dimethoxyyquinazoline ([I-125]AS
A-P). Mefloquine, a quinolinemethanol antimalarial drug, was shown to
inhibit the labelling of P-glycoprotein with an efficiency similar to
that for verapamil, a known chemosensitizer. By contrast, chloroquine
competed poorly for the binding site on P-glycoprotein. Mefloquine als
o inhibited the functional activity of P-glycoprotein. It decreased th
e rates of extrusion of [H-3]vinblastine and the fluorescent dyes, flu
o-3 acetomethoxy ester and rhodamine 123, from drug-resistant cells an
d decreased the level of resistance of these cells to vinblastine. The
ability of mefloquine to inhibit P-glycoprotein function may be invol
ved in the neurotoxic side-effects occasionally associated with the us
e of mefloquine as an antimalarial drug. Copyright (C) 1996 Elsevier S
cience Inc.